Primary hyperparathyroidism Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languagePrimary hyperparathyroidism MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:27 Aug 2023Last updated:20 Sep 2023SummaryDiagnosis of primary hyperparathyroidism is confirmed biochemically with synchronous normal, but examination of the neck is essential to look for a hard, dense mass, suggestive of parathyroid carcinoma.Parathyroidectomy is the only definitive cure. Monitoring is an option for patients who have mild hypercalcaemia without surgical indications, which include lack of ensured follow-up, renal stones, impaired renal function, or osteoporosis.DefinitionPrimary hyperparathyroidism (PHPT
Calcifediol (secondary hyperparathyroidism) - Benefit assessment according to '35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Calcifediol (sekundärer Hyperparathyreoidismus) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 25 April 2022). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-09 Calcifediol (secondary hyperparathyroidism) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A22-09 Version 1.0 Calcifediol (secondary hyperparathyroidism
What are the indications for parathyroidectomy in patients with asymptomatic primary hyperparathyroidism? Clinical CorrelationsCHIEFS’ INQUIRY CORNER-9/13/22September 13, 2022CHIEFS' INQUIRY CORNER 2 MIN READ | TWITTER | FACEBOOK | EMAILChief residents of the NYU Langone Internal Medicine Residency give quick-and-easy, evidence-based answers to interesting questions posed by house staff, both in their clinics and on the wards.Click to toggle the answers!Bellevue Outpatient: What are the indications for parathyroidectomy in patients with asymptomatic primary hyperparathyroidism?Bellevue Inpatient: What are treatments for acute dystonia? Tisch-Kimmel Inpatient: How does Glucagon treat beta-blocker toxicity?Share: Twitter | Facebook | EmailSites We FollowACP Internist BlogBMJ BlogsClinical Cases
Chronotherapy with Cinacalcet has a striking effect on inhibition of parathyroid gland proliferation in rats with secondary hyperparathyroidism. Secondary hyperparathyroidism (sHPT) is a significant clinical complication of CKD leading to bone abnormalities and cardiovascular disease. Current treatment based on activating the parathyroid calcium-sensing receptor (CaSR) using calcimimetics
Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel. Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD). Many recommendations in the Kidney Disease Improving Global Outcomes (KDIGO) CKD-mineral and bone disorder guidelines are supported by modest evidence and predate the approval
Cinacalcet hydrochloride (Mimpara) - Secondary hyperparathyroidism (HPT) or Parathyroid carcinoma and primary HPT in adults Published 9 March 2020 www.scottishmedicines.org.uk Statement of advice SMC2275 cinacalcet hydrochloride 1mg, 2.5mg and 5mg granules in capsules for opening (Mimpara®) Amgen Ltd 7 February 2020 Advice context: No part of this advice may be used without in capsules for opening (Mimpara®) is not recommended for use within NHSScotland. Indication under review: Secondary hyperparathyroidism (HPT) Treatment of secondary HPT in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Treatment of secondary HPT in children aged 3 years and older with ESRD on maintenance dialysis therapy in whom secondary HPT
Cinacalcet For The Treatment Of Secondary Hyperparathyroidism In End Stage Renal Failure And Economic Evaluation Portal Rasmi Kementerian Kesihatan Malaysia Portal RasmiKEMENTERIAN KESIHATAN MALAYSIA DataTerbukaSearchFunctionSearchFunctionprivacypolicyfeedbackformpdpaBroadcastPengenalan KamiBeritaSoalan LazimPublicationPekelilingHubungi KamiW3CHubungi KamiSoalan LazimAduan & Maklum Tajuk Cinacalcet For The Treatment Of Secondary Hyperparathyroidism In End Stage Renal Failure And Economic Evaluation Tahun 2020 Lampiran-lampiran
Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PROCEED Pilot Randomized Trial Parathyroidectomy and calcimimetics have been used to reduce fracture risk in patients with kidney failure and advanced secondary hyperparathyroidism (SHPT), but direct comparisons of these treatment
Italian Guidelines for the Management of Sporadic Primary Hyperparathyroidism This guideline (GL) is aimed at providing a clinical practice reference for the management of sporadic primary hyperparathyroidism (PHPT) in adults. PHPT management in pregnancy was not considered. This GL has been developed following the methods described in the Manual of the Italian National Guideline System
Normocalcemic primary hyperparathyroidism is an early stage of primary hyperparathyroidism according to fibroblast growth factor 23 level. Normocalcemic primary hyperparathyroidism is a variant of primary hyperparathyroidism with consistently normal albumin-adjusted or free-ionized calcium levels. It may be an early stage of classic primary hyperparathyroidism or could represent primary kidney or bone disorder characterized by permanent elevation of PTH level. The study aims to compare the FGF-23 levels in patients with PHPT, NPHPT, and normal calcium and PTH levels. Our study included patients who were referred to the endocrinology clinic with a presumptive diagnosis of primary hyperparathyroidism, an isolated increased level of PTH, or reduced bone densitometry. For each patient, we
US-Guided Thermal Ablation for Secondary Hyperparathyroidism: A Prospective Multicenter Study. Background Interest in microwave ablation (MWA) and radiofrequency ablation (RFA) use for treating secondary hyperparathyroidism (SHPT) is rising; however, ablation outcomes in patients with SHPT are not well characterized. Purpose To assess the response of parathyroid hormone (PTH), calcium
Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome. Establishing genotype-phenotype correlations in disorders of hereditary endocrine neoplasia is important for clinical screening, genetic counseling, prognostication, surveillance, and surgical strategy, and may also provide clues about disease pathogenesis. Important genotype-phenotype correlations are recognized , for example, in pheochromocytoma/paraganglioma and multiple endocrine neoplasia type 2A. The presence of such correlations has been less clear in other familial endocrine disorders associated with primary hyperparathyroidism including multiple endocrine neoplasia type 1 (MEN1), and the hyperparathyroidism-jaw tumor syndrome (HPT-JT). Characteristic features of HPT-JT, apart from fibro-osseous jaw tumors
Comparison of the two treatment methods in primary hyperparathyroidism due to solitary parathyroid adenoma, Ultrasound-guided percutaneous alcohol ablation vs. parathyroidectomy: a randomized controlled trial. Primary hyperparathyroidism (pHPT) is the third most common endocrine system disorder. Parathyroidectomy (PTx) is the gold standard of care in symptomatic patients. Patients who
Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (ERC) in non-dialysis chronic kidney disease (ND-CKD). Sustained 30% reductions of intact parathyroid hormone (iPTH) with ERC are associated with slower decline in estimated glomerular filtration rate (eGFR) in ND-CKD patients with SHPT. Such iPTH
Parathyroid near-infrared autofluorescence use for parathyroidectomy in mild primary hyperparathyroidism: Results from a randomized monocentric trial. Multiglandular parathyroid disease, which is particularly frequent in patients with mild primary hyperparathyroidism, is a surgical challenge requiring bilateral cervicotomy with 4-gland exploration. Near-infrared autofluorescence of the parathyroid is increasingly used to prevent hypocalcemia after total thyroidectomy. However, its utility in decreasing operating time and aiding parathyroid identification during bilateral 4-gland exploration remains debated. In our prospective trial, we enrolled consecutive patients with sporadic mild primary hyperparathyroidism (serum calcium <2.85 mmol/L with elevated or nonadapted serum parathyroid
The Landmark Series: Management of Primary Hyperparathyroidism. Surgery is the only definitive treatment for primary hyperparathyroidism (PHPT). The surgical management of PHPT has evolved over the past several decades in response to the continually growing body of evidence supporting its effectiveness in both symptomatic and asymptomatic disease. As imaging modalities for localization, operative
The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study. Denosumab is approved for treating hypercalcemia of malignancy, but data on its efficacy for hypercalcemia related to primary hyperparathyroidism (PHPT) are limited. To compare the efficacy and safety of denosumab with zoledronic acid in PHPT-related hypercalcemia. We
Increase in serum parathyroid hormone level intraoperatively after parathyroidectomy for primary hyperparathyroidism. To evaluate the significance of increased of intraoperative parathyroid hormone(IOPTH) 10 min after parathyroidectomy in primary hyperparathyroidism. All patients underwent parathyroidectomy were retrospectively included. Following the results of IOPTH, three groups were defined